Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 19.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Newly diagnosed and confirmed Stage IIIB/IV NSCLC~* Previously treated NSCLC with asymptomatic brain metastases (eligible for Arm M) See additional details below~* Men and women aged ≥18 years~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Subject must be chemotherapy naive (except Arm D, K, L and M). Prior use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is acceptable. For Arms D, K, and L, subjects must be non-progressors within 42 days after completion of first-line treatment with ≥4 cycles of Platinum Doublet chemotherapy with or without Bevacizumab. See below for Arm M~* Either a formalin fixed tissue block or a minimum of 10 slides of tumor sample (archived or fresh) must be available for biomarker evaluation (a local pathologist must review for adequacy of sampling)~* Life expectancy of at least 3 months~* Prior radiotherapy must have been completed at least 2 weeks prior to study entry~For Arm M:~* No more than 4 brain metastases~* Each brain metastases ≤3 cm in size~* No evidence of cerebral edema~* Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ≥10 days prior to initiation of study treatment~* At least 1 measurable target brain lesion \>0.5 cm and no larger than 3 cm in diameter and/or 2 measurable brain target lesions \>0.3 cm~* No prior radiation therapy, surgery, or other local therapy for target brain lesions~* Must have received at least one prior systemic anticancer therapy for NSCLC~Exclusion Criteria:~* Subjects with symptomatic brain metastases, spinal cord compression, or intractable back pain due to a compressive or destructive mass~* Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy~* Any active or history of a known autoimmune disease~* Subjects with previous malignancies (except non-melanoma skin cancers, in situ bladder cancer, gastric, or colon cancers or cervical cancers/dysplasia, or breast carcinoma in situ) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period~* History of Grade ≥2 neuropathy~* Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Nivolumab + Gemcitabine + Cisplatin (Type: EXPERIMENTAL): Nivolumab solution intravenously every 3 weeks until progressive disease (PD) or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Gemcitabine solution intravenously on Day 1 and Day 8 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles
- Arm B: Nivolumab + Pemetrexed + Cisplatin (Type: EXPERIMENTAL): Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Pemetrexed solution intravenously on Day 1 of every cycle for 4 cycles~Cisplatin solution intravenously on Day 1 of each cycle for 4 cycles
- Arm C: Nivolumab + Paclitaxel + Carboplatin (Type: EXPERIMENTAL): Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Paclitaxel solution intravenously on Day 1 of every cycle for 4 cycles~Carboplatin area under curve (AUC) 6 solution intravenously on Day 1 of every cycle for 4 cycles
- Arm D: Nivolumab + Bevacizumab maintenance (Type: EXPERIMENTAL): Nivolumab solution intravenously every 3 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Bevacizumab administered prior to intravenous infusion on Cycle 1 Day 1 followed by intravenous infusion every 3 weeks on Cycle 2 onwards and until PD or discontinuation due to toxicity
- Arm E: Nivolumab + Erlotinib (Type: EXPERIMENTAL): Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered prior to chemotherapy on Day 1 of each cycle~Erlotinib tablet by mouth daily until PD or discontinuation due to toxicity
- Arm F: Nivolumab (Type: EXPERIMENTAL): Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes
- Arm G: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): In Squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered until PD or discontinuation due to toxicity
- Arm H: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity
- Arm I: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): In squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity
- Arm J: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): In non-squamous histology subjects (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity
- Arm K: Nivolumab (Type: EXPERIMENTAL): In squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered as switch maintenance therapy. A cycle is 2 weeks
- Arm L: Nivolumab (Type: EXPERIMENTAL): In non-squamous histology subjects (NSCLC)~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered over 60 minutes as switch maintenance therapy. A cycle is 2 weeks
- Arm M: Nivolumab (Type: EXPERIMENTAL): NSCLC subjects with untreated, asymptomatic brain metastases and have no evidence of cerebral edema~Nivolumab solution intravenously every 2 weeks until PD or discontinuation due to toxicity. Administered for up to an hour as monotherapy. A cycle is 2 weeks
- Arm N: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): In subjects with any histology (NSCLC)~Nivolumab solution administered intravenously prior to Ipilimumab on Day 1 of each cycle. Combination regimen will be provided for 4 cycles~Ipilimumab solution administered intravenously on Day 1 of each cycle, for 4 cycles~Followed by Nivolumab administered every 2 weeks until PD or discontinuation due to toxicity
- Arm O: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity
- Arm P: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity
- Arm Q: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity
- Arm R: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity
- Arm S: Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab at specified dose/schedule until PD or discontinuation due to toxicity~Ipilimumab at specified dose/schedule until PD or discontinuation due to toxicity

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete